Thanks RVXOT. I am happy to see that the Phase 2b clinical development of ZEN-3694 + enzalutamide in mCRPC is proceeding, one way or another. Personally I would rather it be a US based trial with Astellas rather than a China based Newsoara trial. So if the plans for the latter are delayed or no longer planned, so be it as long as the Astellas trial proceeds.
BDAZÂ